share_log

科倫博泰生物-B:自願公告核心產品蘆康沙妥珠單抗(sac-TMT)於2024年美國臨床腫瘤學會年會上公佈的研究成果

SKB BIO-B: VOLUNTARY ANNOUNCEMENTSTUDY RESULTS FOR CORE PRODUCT SACITUZUMAB TIRUMOTECAN(SAC-TMT) AT 2024 ASCO ANNUAL MEETING

Hong Kong Stock Exchange ·  May 23 18:06
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more